Lialda FDA Approval History
FDA Approved: Yes (First approved January 16, 2007)
Brand name: Lialda
Generic name: mesalamine
Dosage form: Delayed Release Tablets
Company: Shire plc
Treatment for: Ulcerative Colitis
Lialda (mesalamine) is a locally acting 5-aminosalicylic acid (5-ASA) indicated for the induction of remission in adults with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis.
Development timeline for Lialda
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.